Regeneration in the digestive tract
The human digestive tract houses a universe of tiny organisms. There are roughly as many bacteria in the gut as there are people living on earth. These microorganisms almost always serve the well-being of their host. They help to digest food, produce vitamins, and train the immune system. In addition, their very presence helps stem the spread of pathogens.
But the intestinal microcosm, also known as the microbiome, is sensitive to disruptions. “When thrown out of balance, there is a risk of infection, excess weight, and diabetes, as well as inflammatory and neurological diseases,” says Dr. Sofia Forslund, who in May this year switched from the European Molecular Biology Lab (EMBL) in Heidelberg to the Max Delbrück Center for Molecular Medicine (MDC) in Berlin to study the complex interactions between humans and microbiomes.
Our study is probably the first to investigate the influence of antibiotics on bacterial gene activity.
Antibiotics leave permanent traces in the gut
In a study published recently in Nature Microbiology, Forslund, together with colleagues from Denmark, Germany, and China, investigated how broad-spectrum antibiotic therapy affects the interaction of gut bacteria. “We were able to show that the microbiome had almost completely recovered six months after drug administration,” says the Swedish researcher. But only “almost”: “Some sensitive bacterial species disappeared completely,” says Forslund.
In the four-day study, the team led by MDC researchers and two scientists from the University of Copenhagen administered a cocktail of three antibiotics (meropenem, gentamicin, and vancomycin) to twelve healthy young men who had agreed to participate. These drugs are mainly used when more common antibiotics no longer work, due to the bacteria already having become resistant to them.
Some types of bacteria survived the drug administration
The researchers then studied their subjects’ microbiomes for six months. By means of DNA sequencing – a method used to determine the structure of the genetic material – they determined which bacterial species were present in the men’s guts, and which genes were present in the bacteria. The team also paid particular attention to resistance genes, with which the microbes defend themselves against drugs. “Our study is probably the first to investigate the influence of antibiotics on bacterial gene activity,” says Forslund.
It was first shown that the gut had not become completely sterile despite the administration of three potent antibiotics, reports the researcher. Among the remaining bacteria, the team even discovered some previously unknown species that have not yet been characterized. Other microbes shrank and turned into spores – a life form in which bacteria can persist for many years in precarious conditions without losing their original properties.
Colorized scanning electron micrograph of Escherichia coli, grown in culture and adhered to a cover slip.
More and more disease-causing pathogens initially appeared
The subsequent repopulation of the gut was gradual. “Similar to when a forest slowly recovers after a fire,” says Forslund. However, according to the researcher, bacteria with disease-causing properties, such as Enterococcus faecalis and Fusobacterium nucleatum, initially appeared more frequently. At the same time, the team was able to identify many virulence factors in the microorganisms – structures and metabolites that are more harmful to humans. “This observation explains why most antibiotics cause gastrointestinal disturbances,” says Forslund.
Over time, however, the intestinal flora normalized again. Bad microbes were increasingly replaced by good bacteria such as the lactic acid-producing bifidobacteria that are instrumental in keeping pathogens away. After six months, the subjects’ microbiome was nearly the same as before. However, more than a few of the earlier bacterial varieties were missing. “As expected, the number of resistance genes in the bacteria also increased,” reports Forslund. Surprisingly, it was not the case that the bacterial species that reappeared most rapidly after antibiotic administration also had the most resistance genes. “This genetic material seems more likely to play a long-term role in gut repopulation,” says the researcher.
The lung microbiome will also be investigated further
“Given the apparently permanent loss of individual species and the increased number of resistance genes, the study shows once again how important it is to administer antibiotics with care,” Forslund emphasizes, adding: “It must also be further explored how to increase future success rates in protecting the sensitive microbiome from damage caused by antibiotics.”
The scientist plans to contribute to this research. For example, the MDC is currently running an observational study through which Forslund wants to find out how longer-term antibiotic treatments affect gut biodiversity – and whether a greater depletion of species increases the risk of obesity and metabolic diseases. She would also like to investigate how often gut bacteria exchange their resistance genes during antibiotic administration. A study investigating the influence of these drugs on the lung microbiome is already in the planning stage.
Reference
Albert Palleja et al. (2018): “Recovery of gut microbiota of healthy adults following antibiotic exposure.” Nature Microbiology 3. doi:10.1038/s41564-018-0257-9
The Max Delbrück Center for Molecular Medicine (MDC)
The Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) is one of the world’s leading biomedical research institutions. Max Delbrück, a Berlin native, was a Nobel laureate and one of the founders of molecular biology. At the MDC’s locations in Berlin-Buch and Mitte, researchers from some 60 countries analyze the human system – investigating the biological foundations of life from its most elementary building blocks to systems-wide mechanisms. By understanding what regulates or disrupts the dynamic equilibrium in a cell, an organ, or the entire body, we can prevent diseases, diagnose them earlier, and stop their progression with tailored therapies. Patients should benefit as soon as possible from basic research discoveries. The MDC therefore supports spin-off creation and participates in collaborative networks. It works in close partnership with Charité – Universitätsmedizin Berlin in the jointly run Experimental and Clinical Research Center (ECRC), the Berlin Institute of Health (BIH) at Charité, and the German Center for Cardiovascular Research (DZHK). Founded in 1992, the MDC today employs 1,600 people and is funded 90 percent by the German federal government and 10 percent by the State of Berlin.
